Table 3.

Summary of retrospective studies describing combining JAK inhibitors in HCT protocols

Reference	# Patients	Study Design	Results	Conclusions
38	100	Retrospective	No adverse impact on early outcomes of HCT	Continuing JAK inhibitor therapy near to start of conditioning therapy is associated with very low risk of withdrawal symptoms
				HCT was delayed in 2 patients due to significant clinical events following JAK 1/2 inhibitor discontinuation: 1 patient developed pulmonary infiltrates and rebound splenomegaly, a second patient experienced fever and hypoxic respiratory failure
47	22	Retrospective	1-y OS of 100% in patients with a good response to ruxolitinib vs 60% in others	Continuing ruxolitinib until conditioning without tapering resulted in no unexpected SAEs
36	14	Retrospective	Engraftment in 13 patients (93%); graft fibrosis (n = 1) and treatment-related sepsis (n = 1)	Tapering ruxolitinib until conditioning did not result in unexpected SAEs
48	11	Retrospective	Good engraftment rates	Differing schedules of ruxolitinib tapering associated with high engraftment rates